VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

NCT03148132 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Retinopathy of Prematurity Both Eyes
Retinal Disease
Premature Birth
Eye Diseases

Interventions

DRUG: Bevacizumab Injection
DRUG: Ranibizumab Ophthalmic

Sponsor

Universidad Autonoma de San Luis Potosí

Collaborators

[object Object]